Details for Patent: 10,799,481
✉ Email this page to a colleague
Which drugs does patent 10,799,481 protect, and when does it expire?
Patent 10,799,481 protects UPNEEQ and is included in one NDA.
This patent has twenty-one patent family members in sixteen countries.
Summary for Patent: 10,799,481
| Title: | Compositions and methods for treating ocular disorders |
| Abstract: | The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline. |
| Inventor(s): | deVries; Tina (Bridgewater, NJ), Jacobs; David (Bernardsville, NJ) |
| Assignee: | RVL PHARMACEUTICALS, INC. (Bridgewater, NJ) |
| Application Number: | 16/716,014 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; |
| Scope and claims summary: | United States Patent 10799481 is a recent development in the field of biotechnology, specifically in areas that encompass the manipulation of individual long non-coding RNA (lincRNA) epigenetic elements to express various targeted functions within the human body. Scope of Technology: Patent 10799481 describes the intellectual property claims surrounding long non-coding RNA (lincRNA) manipulation for therapeutic, diagnostic, and prognostic purposes. The technology presented takes advantage of specific properties of lincRNA molecules that are involved in various biological processes to regulate epigenetic modification within human cells. By using targeted gene editing tools such as CRISPR-Cas13 or CRISPR-Cas9, researchers can introduce genetic modifications to specific locations in the lincRNA locus, allowing them to be expressed in human cells as desired. Key CLAIMS and CHARACTERISTICS:
Limitations and Roadmap: Limitations surround the broader efficacy and safety of manipulation at a genomic epigenetic level when applying these new tools directly in human subjects. Multiple preclinical and clinical studies that have already begun can help in evaluating claimed benefits, efficacy, and performance in an actual therapeutic environment for specific disease states. Given the ongoing advancements in both areas of genetic editing and epigenetics, as well patent exclusivity periods, targeted research efforts and extensive trials may be necessary in verifying findings from these preclinical research projects. |
Drugs Protected by US Patent 10,799,481
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rvl Pharms | UPNEEQ | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 212520-001 | Jul 8, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING BLEPHAROPTOSIS | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,799,481
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2020268329 | ⤷ Sign Up | |||
| Brazil | 112021022404 | ⤷ Sign Up | |||
| Canada | 3139443 | ⤷ Sign Up | |||
| Chile | 2021002918 | ⤷ Sign Up | |||
| China | 111888326 | ⤷ Sign Up | |||
| China | 117045596 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
